Showing results (1-10 of 69) with videos related to
Sort By:
Pageof 7
Cardiovascular & Hematological Agents in Medicinal Chemistry|July 26, 2012
Incretins and preservation of endothelial functionJuraj KoskaEndocrine Regulations|September 5, 2002
Effect of body composition on indices of insulin sensitivity and beta-cell function in healthy menZofia Cervenakova, Lucia Ksinantova, Juraj KoskaCardiovascular Diabetology|July 9, 2011
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretinsSameer Ansar, Juraj Koska, Peter D ReavenMetabolism: Clinical and Experimental|December 3, 2014
Dietary models of insulin resistanceJames Deer, Juraj Koska, Marlies Ozias, et al.Diabetes & Vascular Disease Research|April 9, 2015
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetesJuraj Koska, Michelle Sands, Camelia Burciu, et al.Diabetes & Vascular Disease Research|April 25, 2019
Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes TrialJin J Zhou, Juraj Koska, Gideon Bahn, et al.The Journal of Clinical Endocrinology and Metabolism|December 28, 2020
Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADTJin J Zhou, Juraj Koska, Gideon Bahn, et al.Metabolic Syndrome and Related Disorders|October 16, 2010
Fetuin-A does not explain ethnic disparity in cardiometabolic risk factors and subclinical atherosclerosis between Hispanics and non-Hispanic whitesIyad Syoufi, Juraj Koska, Matthew J Budoff, et al.Neuroimmunomodulation|April 7, 2004
Pharmacological hyperprolactinemia attenuates hydrocortisone-induced expression of CD11b on human CD8+ cells in vivoRichard Imrich, Elena Tibenska, Juraj Koska, et al.Recent Patents on Cardiovascular Drug Discovery|January 28, 2012
Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activityAngelica J Motta, Juraj Koska, Peter Reaven, et al.Pageof 7